Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 5:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–14 of 14 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Quark Pharmaceuticals Clear all
Terminated Phase 3 Interventional

QPI-1002 Phase 3 for Prevention of Major Adverse Kidney Events (MAKE) in Subjects at High Risk for AKI Following Cardiac Surgery

NCT03510897
View directory record Official record
Conditions
Cardiac Surgery
Interventions
teprasiran, Placebo
Drug
Lead sponsor
Quark Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,043 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
36
States / cities
Birmingham, Alabama • Los Angeles, California • New Haven, Connecticut + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2021 · Synced Oct 5, 2026, 5:22 AM EDT
Completed Phase 2 Interventional

Phase II Open Label Multicenter Study For Age Related Macular Degeneration Comparing PF-04523655 Versus Lucentis In The Treatment Of Subjects With CNV (MONET Study).

NCT00713518
View directory record Official record
Conditions
Age Related Macular Degeneration
Interventions
0.5 mg ranibizumab, 3 mg PF-04523655, 1 mg PF-04523655
Drug
Lead sponsor
Quark Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
7
States / cities
San Francisco, California • Fort Myers, Florida • Winter Haven, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2012 · Synced Oct 5, 2026, 5:22 AM EDT
Completed Phase 1 Interventional

Safety Study of a Single IVT Injection of QPI-1007 in Chronic Optic Nerve Atrophy and Recent Onset NAION Patients

NCT01064505
View directory record Official record
Conditions
Optic Atrophy, Non-arteritic Anterior Ischemic Optic Neuropathy
Interventions
QPI-1007 at various doses
Drug
Lead sponsor
Quark Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
22
States / cities
Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated May 13, 2013 · Synced Oct 5, 2026, 5:22 AM EDT
Completed Phase 1 Interventional

A Dose Escalation and Safety Study of I5NP in Patients Undergoing Major Cardiovascular Surgery

NCT00554359
View directory record Official record
Conditions
Injury of Kidney, Acute Renal Failure
Interventions
I5NP (a small interfering RNA), placebo
Drug
Lead sponsor
Quark Pharmaceuticals
Industry
Eligibility
21 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
6
States / cities
Washington D.C., District of Columbia • Boston, Massachusetts • Cleveland, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2011 · Synced Oct 5, 2026, 5:22 AM EDT
Completed Phase 1 Interventional

Study of PF-04523655 (REDD14NP) In Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (Wet AMD)

NCT00725686
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
PF-04523655
Drug
Lead sponsor
Quark Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
8
States / cities
Beverly Hills, California • Pasadena, California • Walnut Creek, California + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2012 · Synced Oct 5, 2026, 5:22 AM EDT
Terminated Phase 2 Interventional

Study Evaluating Efficacy and Safety of PF-04523655 Versus Laser in Subjects With Diabetic Macular Edema

NCT00701181
View directory record Official record
Conditions
Diabetic Retinopathy, Diabetes Complications
Interventions
Laser Treatment, PF-04523655 high, PF-04523655 middle, PF-04523655 low
Procedure · Drug
Lead sponsor
Quark Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
26
States / cities
Mesa, Arizona • Meza, Arizona • Peoria, Arizona + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2012 · Synced Oct 5, 2026, 5:22 AM EDT
Terminated Phase 1 Interventional

A Dose Escalation and Safety Study of I5NP to Prevent Acute Kidney Injury (AKI) in Patients at High Risk of AKI Undergoing Major Cardiovascular Surgery (QRK.004)

NCT00683553
View directory record Official record
Conditions
Acute Renal Failure, Acute Kidney Injury
Interventions
I5NP, Placebo
Drug
Lead sponsor
Quark Pharmaceuticals
Industry
Eligibility
21 Years to 85 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
10
States / cities
Birmingham, Alabama • Phoenix, Arizona • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2010 · Synced Oct 5, 2026, 5:22 AM EDT
Terminated No phase listed Observational

Evaluation of Renal Function in Subjects Who Had Undergone Cardiac Surgery

NCT04654221
View directory record Official record
Conditions
Cardiac Surgery
Interventions
mGFR by iohexol clearance
Diagnostic Test
Lead sponsor
Quark Pharmaceuticals
Industry
Eligibility
45 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
6
States / cities
Mobile, Alabama • Covina, California • Northridge, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2021 · Synced Oct 5, 2026, 5:22 AM EDT
Completed Phase 2 Interventional

PF-04523655 Dose Escalation Study, and Evaluation of PF-04523655 With/Without Ranibizumab in Diabetic Macular Edema (DME)

NCT01445899
View directory record Official record
Conditions
Choroidal Neovascularization, Diabetic Retinopathy, Diabetic Macular Edema
Interventions
PF-04523655 (Stratum I), ranibizumab, PF-04523655 (Stratum II)
Drug
Lead sponsor
Quark Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
20
States / cities
Phoenix, Arizona • Arcadia, California • Beverly Hills, California + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2015 · Synced Oct 5, 2026, 5:22 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate Efficacy and Safety of QPI-1002 for Prevention of Acute Kidney Injury Following Cardiac Surgery

NCT02610283
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
QPI-1002, Placebo
Drug
Lead sponsor
Quark Pharmaceuticals
Industry
Eligibility
45 Years and older
Enrollment
341 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
20
States / cities
Tucson, Arizona • Gainesville, Florida • Jacksonville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2019 · Synced Oct 5, 2026, 5:22 AM EDT
Completed Phase 2 Interventional

Phase IIA Double-Masked Randomized Sham-Controlled Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Subjects With Acute Primary Angle-Closure Glaucoma (APACG)

NCT01965106
View directory record Official record
Conditions
Glaucoma, Angle-closure, Primary, Acute
Interventions
QPI-1007 Injection, (including placebo)
Drug
Lead sponsor
Quark Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
4
States / cities
Orange, California • Pasadena, California • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2017 · Synced Oct 5, 2026, 5:22 AM EDT
Completed Phase 1Phase 2 Interventional

I5NP for Prophylaxis of Delayed Graft Function in Kidney Transplantation

NCT00802347
View directory record Official record
Conditions
Delayed Graft Function, Other Complication of Kidney Transplant
Interventions
I5NP, Saline
Drug
Lead sponsor
Quark Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
374 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
33
States / cities
Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2014 · Synced Oct 5, 2026, 5:22 AM EDT
Terminated Phase 2Phase 3 Interventional

Phase 2/3, Randomized, Double-Masked, Sham-Controlled Trial of QPI-1007 in Subjects With Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)

NCT02341560
View directory record Official record
Conditions
Non Arteritic Anterior Ischemic Optic Neuropathy
Interventions
QPI-1007 Injection - 1.5 mg, QPI-1007 Injection - 3.0 mg, Sham Injection Procedure
Drug · Other
Lead sponsor
Quark Pharmaceuticals
Industry
Eligibility
50 Years to 80 Years
Enrollment
732 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
44
States / cities
Little Rock, Arkansas • Loma Linda, California • Los Angeles, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2020 · Synced Oct 5, 2026, 5:22 AM EDT
Completed Phase 3 Interventional

QPI-1002 for Prevention of Delayed Graft Function in Recipients of an Older Donor Kidney Transplant

NCT02610296
View directory record Official record
Conditions
Delayed Graft Function
Interventions
QPI-1002, Placebo
Drug · Other
Lead sponsor
Quark Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
594 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
36
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated May 13, 2020 · Synced Oct 5, 2026, 5:22 AM EDT